Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr

Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023

BenevolentAI appoints former Bayer R&D head Dr. Joerg Moeller as CEO

An accomplished R&D leader and champion of the application of AI to drug discovery

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023

Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients

Novo Holdings expands portfolio in cancer diagnostics

Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer

Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator